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Objectives. This study sought to define the relation between
muscle function and bulk in chronic heart failure (HF) and to
explore the association between muscle function and bulk and
exercise capacity.
Background. Skeletal muscle abnormalities have been postu-
lated as determinants of exercise capacity in chronic HF. Previ-
ously, muscle function in chronic HF has been evaluated in
relatively small numbers of patients and with variable results,
with little account being taken of the effects of muscle wasting.
Methods. One hundred male patients with chronic HF and 31
healthy male control subjects were studied. They were matched for
age (59.0 6 1.0 vs. 58.7 6 1.7 years [mean 6 SEM]) and body
mass index (26.6 6 0.4 vs. 26.3 6 0.7 kg/m2). We assessed
maximal treadmill oxygen consumption (V˙O2), quadriceps maxi-
mal isometric strength, fatigue (20-min protocol, expressed in
baseline maximal strength) and computed tomographic cross-
sectional area (CSA) at midthigh.
Results. Peak V˙O2 was lower in patients (18.0 6 0.6 vs. 33.3 6
1.4 ml/min per kg, p < 0.0001), although both groups achieved a
similar respiratory exchange ratio at peak exercise (1.15 6 0.01
vs. 1.19 6 0.03, p 5 0.13). Quadriceps (582 vs. 652 cm2, p < 0.05)
and total leg muscle CSA (1,153 vs. 1,304 cm2, p < 0.005) were
lower in patients with chronic HF. Patients were weaker than
control subjects (357 6 12 vs. 434 6 18 N, p < 0.005) and also
exhibited greater fatigue at 20 min (79.1% vs. 92.1% of baseline
value, p < 0.0001). After correcting strength for quadriceps CSA,
significant differences persisted (5.9 6 0.2 vs. 7.0 6 0.3 N/cm2, p <
0.005), indicating reduced strength per unit muscle. In patients,
but not control subjects, muscle CSA significantly correlated with
peak absolute V˙O2 (R 5 0.66, p < 0.0001) and is an independent
predictor of peak absolute V˙O2.
Conclusions. Patients with chronic HF have reduced quadri-
ceps maximal isometric strength. This weakness occurs as a result
of both quantitative and qualitative abnormalities of the muscle.
With increasing exercise limitation there is increasing muscle
weakness. This progressive weakness occurs predominantly as a
result of loss of quadriceps bulk. In patients, this muscular
atrophy becomes a major determinant of exercise capacity.
(J Am Coll Cardiol 1997;30:1758–64)
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The processes by which exercise is limited in chronic heart
failure (HF) remain unclear. There is poor correlation be-
tween exercise capacity and central hemodynamic measure-
ments (1–3). Acute improvements in cardiac function do not
result in an immediate improvement in exercise capacity (4–7).
Exercise tolerance is not determined directly by the extent of
the central hemodynamic disturbance (8). As a consequence of
these observations, potential peripheral determinants of exer-
cise capacity have been sought.
The skeletal musculature has been extensively investigated.
Muscle bulk is known to be reduced in chronic HF (9), and
general muscle and fat tissue wasting (i.e., cachexia) has
recently been shown (10) to predict impaired survival in
chronic HF. Abnormalities of muscle function (11–14), histo-
logic features (15,16) and metabolism (17,18) have all been
described. We and others have postulated that these muscle
changes are part of the syndrome of chronic HF and contribute
to the symptoms of these patients (19–21). If muscle changes
are central to the exercise limitation seen in CHF, then there
would be important clinical implications. The poor link be-
tween symptoms and hemodynamic disturbance would be
explained, and a novel area for therapeutic intervention would
arise.
Abnormal muscle function can lead to exercise intolerance.
If this were true in chronic HF, a reasonable correlation
between exercise capacity and indexes of muscle function
would be expected. Although a reduction in muscle bulk has
been described (9), most groups have found preservation of
From the *Department of Cardiac Medicine, National Heart and Lung
Institute, Imperial College of Science, Technology and Medicine, London,
England, United Kingdom; and †Department of Internal Medicine III/
Cardiology, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
Dr. Harrington was supported by the Robert Luff Foundation, London. Dr.
Anker was supported by a research fellowship of the European Society of
Cardiology, Rotterdam, The Netherlands and by a grant from the Ernst und
Bertha Grimmke-Stiftung, Du¨sseldorf, Germany.
Manuscript received November 7, 1996; revised manuscript received August
11, 1997, accepted August 25, 1997.
Address for correspondence: Dr. Stefan D. Anker, Department of Cardiac
Medicine, National Heart and Lung Institute, Imperial College of Science,
Technology and Medicine, Dovehouse Street, London, SW3 6LY, England,
United Kingdom. E-mail: s.anker@ic.ac.uk.
JACC Vol. 30, No. 7
December 1997:1758–64
1758
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00381-1
maximal strength (14,22). Two groups have found normal
strength per unit area in the quadriceps (i.e., that strength is
reduced in proportion to the wasting of this muscle) (12,14).
Nevertheless, Buller et al. (12) described reduced, while
Minotti et al. (14) reported preserved maximal isokinetic
strength. Thus, the existence and extent of weakness and the
mechanism by which it may develop are unclear. Because all
studies to date have been of limited size (maximum of 21
patients studied), the purpose of the present study was to
investigate the relation between muscle strength, muscle bulk,
muscle fatigue and maximal oxygen consumption in a large
group of patients with chronic HF.
Methods
Patients. We studied 100 male patients with chronic HF
matched for age and body mass index (BMI) with 31 healthy
male control subjects (Table 1). The diagnosis of chronic HF
was based on the combination of symptomatic exercise intol-
erance and objective evidence of impairment of left ventricular
systolic function on echocardiography or radionuclide ven-
triculography (mean left ventricular ejection fraction [LVEF]
26 6 2%). Only patients with chronic HF of at least 6 months
in duration due to ischemic heart disease (n 5 62) or idio-
pathic dilated cardiomyopathy (n 5 38) were studied. Twelve
patients were in New York Heart Association functional class
I; 39 were in class II; 39 were in class III; and 10 were in
class IV. Patients were treated with combinations of diuretic
drugs (97%, furosemide equivalent dose 100 6 9 mg/day),
angiotensin-converting enzyme (ACE) inhibitors (87%), aspi-
rin (37%), warfarin (29%), digoxin (28%), oral nitrates (26%)
or calcium antagonists (2%). Because several drugs have a
significant impact on exercise performance, patients that were
treated with ACE inhibitors or digoxin had to be taking these
drugs for at least 3 months before investigation. All patients
had been clinically stable and taking unchanged medication for
at least 1 month before study and on the day of investigation
had no evidence of fluid retention (peripheral or pulmonary
edema or ascites). Patients with chronic lung disease, neuro-
muscular disease or exercise-limiting angina were excluded
from the study. Healthy control subjects were recruited from
hospital staff and their friends. All subjects gave written
informed consent, and the study was approved by the local
ethics committee.
Study design. All subjects performed a maximal cardiopul-
monary exercise test and an assessment of maximal isometric
quadriceps strength. In 93 of 100 patients, LVEF was deter-
mined using radionuclide ventriculography. Computed tomo-
graphic (CT) scans were acquired to enable an estimate of
muscle bulk in all but 17 patients and 6 control subjects.
Quadriceps fatigue could not be determined in 18 patients and
2 control subjects for technical reasons.
Cardiopulmonary exercise testing. Subjects performed a
symptom-limited treadmill exercise test to assess peak oxygen
consumption (V˙O2). A standard Bruce protocol with the
addition of a “stage 0” (3 min, 1 mph, 5% gradient) was used.
During exercise, subjects breathed through a mouthpiece and
a one-way valve attached to a mass spectrometer (Amis 2000
system, Innovision, Odense, Denmark). Using a standard inert
gas dilution technique, this allowed on-line measurement of
metabolic gas exchange and minute ventilation every 10 s (23).
Subjects were instructed and encouraged to exercise to their
maximal capacity.
Muscle function. Muscle function was assessed using a
previously described protocol (12). Subjects were positioned in
a rigid frame. For each leg the best of three voluntary isometric
contractions was taken as the maximal contraction. Subjects
were encouraged to achieve a plateau in force generated, and
maximal effort was confirmed by the absence of a superim-
posed muscular twitch induced by a 1-ms, 1-Hz electrical
stimulus delivered to the quadriceps. If not indicated otherwise
we report the results of strength and muscle mass of the
weaker leg. After establishing the strongest leg, patients were
asked to complete a fatiguing protocol with that leg. Forty
seconds of repeated contractions at 30% to 40% of the
previous maximum (every 2 s according to a acoustic signal
given by a timer) followed by 20 s of rest was repeated in 1-min
cycles for 20 min with reevaluation of maximal strength after
each 5 min. Fatigue was then expressed in percent strength of
baseline maximal strength for each time point.
Muscle bulk. Using ultrafast CT (Imatron), a single slice
was obtained at the midfemur level (taken as one-eighth of the
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
BMI 5 body mass index
CSA 5 cross-sectional area
CT 5 computed tomography (tomographic)
HF 5 heart failure
LVEF 5 left ventricular ejection fraction
SC 5 standardized coefficient
V˙O2 5 oxygen consumption
Table 1. Clinical Characteristics and Exercise Performance Data
Patients With
Chronic HF
(n 5 100)
Control
Subjects
(n 5 31)
p
Value
Age (yr) 59.0 6 1.0 58.7 6 1.7 0.91
BMI (kg/m2) 26.6 6 0.4 26.3 6 0.7 0.80
Peak V˙O2 (ml/min per kg) 18.0 6 0.6 33.3 6 1.4 , 0.0001
Absolute V˙O2 (ml/min) 1,445 6 56 2,668 6 118 , 0.0001
Rest pulse (beats/min) 82 6 2 70 6 3 0.004
Peak pulse (beats/min) 140 6 3 162 6 4 0.003
Rest SBP (mm Hg) 117 6 2 133 6 4 0.004
Rest DBP (mm Hg) 74 6 1 82 6 2 0.02
Peak SBP (mm Hg) 145 6 3 190 6 5 , 0.0001
Peak DBP (mm Hg) 78 6 3 82 6 2 0.33
Data presented are mean value 6 SEM. BMI 5 body mass index; DBP 5
diastolic blood pressure; HF 5 heart failure; SBP 5 systolic blood pressure;
V˙O2 5 oxygen consumption.
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patient’s height measured from the most distal part of the
femur). The cross-sectional area (CSA) of the total thigh,
quadriceps muscle and three other major thigh muscles (ham-
strings, sartorious, gracilis) was measured. This area was
assessed by semiautomatic generation of an outline of the area
of interest using the console software in the CT scanner.
Statistical methods. Results are presented as mean
value 6 SEM. Comparison between patients and control
subjects was made using unpaired Student t tests. Subgroup
comparisons were made using analysis of variance (ANOVA);
when ANOVA showed significant differences, the Fisher post
hoc test was applied. To analyze relations between variables,
simple linear regression (least square method) was performed.
To analyze the predictors of quadriceps muscle strength and
exercise capacity, we analyzed these variables in multivariate
analysis as dependent variables in relation to important clinical
and pathophysiologic measures that were entered as indepen-
dent variables (standard coefficients and the adjusted joint R2
values are also reported). A commercially available statistical
software package was used (Statview 4.5). A value ,0.05 was
considered statistically significant.
Results
Exercise data. Exercise performance data are summarized
in Table 1. Exercise time was significantly shorter (p , 0.0001)
and peak V˙O2 significantly lower in patients, whether corrected
for body weight or expressed as absolute V˙O2 (both p ,
0.0001). However, both patients and control subjects achieved
similar respiratory exchange ratios at peak exercise (1.15 6
0.01 vs. 1.19 6 0.03, p 5 0.13).
Muscle function and bulk. Data for muscle function and
muscle bulk for the weaker leg are presented in Table 2,
although in all cases similar differences were found when data
from the stronger leg were analyzed. There was no difference
in thigh CSA when patients and control subjects were com-
pared (p 5 0.43). Quadriceps CSA was significantly lower in
patients (weaker leg: 211%, p 5 0.021; stronger leg: 212%,
p 5 0.010), as was total muscle CSA (calculated by adding
quadriceps 1 hamstrings 1 gracilis 1 sartorious) (weaker leg:
212%; stronger leg: 212%, both p 5 0.009). Patients were
significantly weaker (weaker leg: 218%, p 5 0.0009; stronger
leg: 215%, p 5 0.002) and more fatigued than control
subjects; the latter was apparent within 5 min (p , 0.05) and
reached greatest statistical significance after 20 min of the
fatiguing protocol (79.1% vs. 92.2% of baseline, p , 0.0001).
Maximal strength generated per unit of quadriceps muscle was
significantly lower in patients (5.9 6 0.2 vs. 7.0 6 0.3 N/cm2,
p , 0.001).
Subgroup analyses: heart failure severity by peak V˙O2 . Pa-
tients were classified into three groups according to the
severity of their exercise limitation: 1) severe (peak V˙O2
,15 ml/min per kg), 2) moderate (peak V˙O2 15 to 20 ml/min
per kg), and 3) mild (peak V˙O2 .20 ml/min per kg). BMI and
LVEF were similar in each of the three patient groups (Table
3). With increased severity of exercise limitation there was
increased quadriceps muscle weakness. There was no differ-
ence in fatigue between groups when assessed after 5 min,
although at 20 min the most severely affected group had
significantly more fatigue than the other two groups. Quadri-
ceps CSA became smaller with increasing disease severity, as
did total leg muscle CSA. However, there was no difference in
strength per unit muscle between the groups (Table 3). There
Table 2. Muscle Bulk and Function in Patients With Chronic Heart
Failure and in Healthy Control Subjects
Patients With
Chronic HF
Control
Subjects
p
Value
CSA (cm2)
Thigh 179 6 6 188 6 5 0.43
Weaker leg
Quadriceps 58 6 2 65 6 2 0.02
Total muscle 115 6 3 131 6 4 0.0090
Stronger leg, total muscle 118 6 3 134 6 4 0.0092
Quadriceps strength (N)
Weaker leg 357 6 11 434 6 18 0.0009
Stronger leg 409 6 12 483 6 18 0.0023
Fatigue (% of baseline)
5 min 85 6 1 90 6 1 0.012
20 min 79 6 1 92 6 2 , 0.0001
Strength/unit muscle (N/cm2)
Weaker leg 5.91 6 0.15 7.02 6 0.29 0.0008
Stronger leg 6.67 6 0.14 7.45 6 0.29 0.012
See Methods for details of assessment. Data presented are mean value 6
SEM. CSA 5 cross-sectional area.
Table 3. Classification According to Heart Failure Severity
Severe
(n 5 33)
Moderate
(n 5 35)
Mild
(n 5 32)
p Value
(ANOVA)
Age (yr) 64 6 2*† 59 6 1‡ 53 6 2 , 0.0001
BMI (kg/m2) 25.8 6 0.7 27.5 6 0.8 26.4 6 0.7 0.27
Peak V˙O2
(ml/min per kg)
12.2 6 0.5 17.4 6 0.3 24.7 6 0.8 , 0.0001
RER at peak exercise 1.15 6 0.03 1.13 6 0.02 1.16 6 0.02 0.80
LVEF (%) 30 6 3 23 6 3 26 6 2 0.16
Strength (N)
Weaker leg 317 6 20† 350 6 17‡ 407 6 19 0.004
Stronger leg 364 6 20† 402 6 19‡ 461 6 21 0.004
Fatigue (% of baseline
strength)
5 min 82 6 2 86 6 2 86 6 2 0.16
20 min 73 6 2*§ 82 6 2 81 6 2 0.02
Quadriceps CSA, weaker
leg (cm2)
53 6 3§ 59 6 3 63 6 3 0.04
Total muscle CSA,
weaker leg (cm2)
103 6 5*† 119 6 5 124 6 5 0.02
Strength/quadriceps unit
area, weaker leg
(N/cm2)
5.9 6 0.2 5.9 6 0.3 5.9 6 0.4 0.96
*p , 0.05, severe versus moderate. †p , 0.01, §p , 0.05, severe versus mild.
‡p , 0.05, moderate versus mild. Data presented are mean value 6 SEM.
ANOVA 5 analysis of variance; LVEF 5 left ventricular ejection fraction;
RER 5 respiratory exchange ratio; other abbreviations as in Tables 1 and 2.
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was a significant difference in age between the three groups. If
the patients in the three groups are aged matched, these results
persist, although the differences in quadriceps and total muscle
CSA become trends only.
A subgroup of 16 patients with chronic HF and a peak V˙O2
$23.0 ml/min per kg was compared with 22 healthy control
subjects with a peak V˙O2 #36.0 ml/kg per min and ,70 years
old. Patients with chronic HF were younger (54 6 2 vs. 61 6 1
year, p , 0.005), and they were more fatigued at 20 min (84 6
3% vs. 92 6 2%, p 5 0.02), but all other markers of exercise
performance (p . 0.17), strength (p . 0.87), muscle size (p .
0.61) and strength per unit muscle (p . 0.11) were not
significantly different.
Subgroup analyses: patients with chronic HF by LVEF or
etiology. When the 93 patients in whom LVEF could be
determined were further classified into three groups according
to LVEF (LVEF ,20% [n 5 38]; LVEF 20% to 35% [n 5 35];
LVEF .35% [n 5 20]), no significant differences for age,
BMI, peak V˙O2, maximal strength of the weaker (p 5 0.43,
ANOVA) or stronger leg (p 5 0.24, ANOVA) or for quadri-
ceps or total muscle CSA of the weaker or stronger leg (p .
0.29, all by ANOVA) or for fatiguability at 5 or 20 min (p .
0.60, both by ANOVA) were found. When the patients were
stratified according to disease etiology, we found that patients
with chronic HF due to ischemic heart disease were somewhat
older (61 6 1 vs. 56 6 2 years) and had a lower peak V˙O2
(16.8 6 0.6 vs. 19.9 6 1.2 ml/min per kg, both p , 0.02), but
muscle size, strength and fatigue were similar (all p . 0.43).
When the eight oldest patients with ischemic heart disease and
the three youngest patients with dilated cardiomyopathy were
excluded from analysis, the mean age was identical (58 years),
and again no differences were found for the measures of
muscle size or function.
Predictors of quadriceps strength. Univariate analysis.
Univariate correlation analysis showed that in both patients
and control subjects, strength correlated significantly with age
(chronic HF: R 5 20.35, p , 0.001; control subjects: R 5
20.57, p , 0.001) and quadriceps CSA (chronic HF: R 5 0.76,
p , 0.0001; control subjects: R 5 0.41, p 5 0.04) (Fig. 1).
Multivariate analysis. In control subjects, multivariate anal-
ysis of the predictors of quadriceps strength of the weaker leg
(dependent variable) with age and quadriceps CSA as inde-
pendent variables showed that age (standard coefficient [SC]
20.64, p 5 0.0002) predicted strength independently of quad-
riceps muscle size (SC 0.26, p 5 0.09) (adjusted joint R2 5
0.55, p 5 0.0001). In patients with chronic HF, multivariate
analysis of the predictors of quadriceps strength with age,
quadriceps CSA, functional class, LVEF and peak V˙O2 showed
that quadriceps CSA (SC 0.70, p , 0.0001) predicted strength
independently of age (SC 20.07, p 5 0.43), functional class
(SC 0.03, p 5 0.80), LVEF (SC 20.01, p 5 0.88) and peak V˙O2
(SC 0.12, p 5 0.24) (adjusted joint R2 5 0.59, p , 0.0001).
Predictors of exercise capacity. To investigate the relation
between subject characteristics, muscle indexes and exercise
capacity, we correlated these variables with weight-adjusted
peak V˙O2 (ml/min per kg) and absolute peak V˙O2 (ml/min) in
the patient and control groups (Table 4, Fig. 2). In patients
with chronic HF, age, quadriceps strength and quadriceps and
thigh muscle CSA correlated with both measurements of peak
V˙O2 (all p , 0.01). In the control group, only age and strength
correlated significantly with both measures of peak V˙O2 (p ,
0.005). Indexes of muscle bulk showed a strong trend toward
correlation with absolute peak V˙O2 in the control group (p ,
0.09). In patients, multivariate analysis of weight adjusted peak
V˙O2 with age, functional class, LVEF and muscle size showed
that age (SC 20.32, p 5 0.0006) and functional class (SC
20.62, p , 0.0001) were the only independent predictors of
weight-adjusted peak V˙O2. LVEF (SC 20.11) and muscle size
(SC 0.06) did not predict weight-adjusted peak V˙O2 (both p .
0.25). In a separate multivariate analysis with only functional
class and age as the independent factors, the joint adjusted R2
value was 0.47 (p , 0.0001); that is, these two factors predicted
47% of the variation of the weight-adjusted peak V˙O2. In
similar multivariate analyses, age (SC 20.29), thigh muscle
CSA (SC 0.48) and functional class (SC 20.44, all p , 0.0001,
joint adjusted R2 5 0.71) were predictors of absolute peak V˙O2
in patients with chronic HF independently of each other. In the
control group, age (independent of muscle size) predicted
absolute peak V˙O2 (age: SC 20.57, p 5 0.0018; muscle size: SC
0.26, p 5 0.12) and weight-adjusted peak V˙O2 (age: SC 20.64,
p 5 0.0009; muscle size: SC 20.02, p 5 0.92).
Discussion
Changes in muscle bulk and strength. To our knowledge,
the present study is the first to demonstrate a significant
reduction in maximal isometric quadriceps strength in a large
Figure 1. Relation between quadriceps strength and quadriceps mus-
cle CSA. Solid squares 5 patients with chronic HF (R 5 0.76, p ,
0.0001, n 5 82); open squares 5 control subjects (R 5 0.41, p , 0.05,
n 5 25).
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group of patients with chronic HF compared with age-matched
healthy control subjects. Our study suggests that this weakness
occurs as a result of two separate processes: wasting and
reduced muscle efficiency.
A strong correlation between maximal strength and quad-
riceps bulk was previously reported in chronic HF (14). We
confirmed this strong correlation in a larger, more diverse
study group. Using single-slice CT scanning, we observed a
reduced quadriceps and total thigh muscle CSA in our pa-
tients. Magnetic resonance imaging and anthropometric tech-
niques (9) have yielded similar results, with investigators
consistently describing wasting and noting its presence even in
mild chronic HF. Weakness should be an inevitable conse-
quence of muscle wasting, unless strength per unit muscle is
increased. Despite previous investigators (14) not always ob-
serving overall muscle weakness, we believe that our study
refutes any possible compensatory increase in strength per unit
muscle. We observed a reduced strength per unit muscle CSA
in the quadriceps, present in even mildly affected patients with
chronic HF. Patients with severe chronic HF have wasting in
addition to a reduction in strength per unit muscle and thus
have more marked weakness. With increasing exercise limita-
tion, quadriceps weakness becomes more severe. This increas-
ing weakness appears largely to be a result of quadriceps
wasting but not to a further reduction in muscle quality. This
finding explains the differences between the observations of
Buller et al. (12) and Minotti et al. (14). Minotti et al. (14)
studied 21 patients with a mean peak V˙O2 of 18 ml/min per kg
(cycle ergometry). Buller et al. (12) studied 10 patients with a
mean peak V˙O2 of 14.8 ml/min per kg (treadmill protocol),
which would have been still lower had they used a cycle
ergometer (24). The difference between the two studies is thus
most likely explained by the marked difference in severity
between the two patient groups. Minotti et al. (14) may not
have found significant weakness because of the small size of
their study group, the lesser severity of chronic HF in their
patients or possibly because their control subjects were weaker.
When we compared patients with CHF and control subjects
with similar exercise capacity, no significant differences in
muscle bulk or function were seen, further suggesting the
importance of leg muscle changes to exercise limitations. To
our knowledge, our observation that strength per unit muscle
is reduced in even mild chronic HF has not been previously
reported. Buller at al. (12) compared strength per unit muscle
in five patients with chronic HF with the normal range
previously reported by Chapman et al. (25). The lack of
difference may reflect differences in the techniques used by
Chapman et al. (25). Chapman et al. (25) used data from both
legs and included some children in the subjects they studied.
The small numbers studied by Buller at al. (12) also make the
detection of a significant difference less likely. Minotti et al.
(14) compared 21 patients with chronic HF with 12 healthy
control subjects. They calculated the maximal CSA from nine
magnetic resonance imaging slices of the thigh. Their obser-
Table 4. Correlates for Peak Oxygen Uptake in Patients With Chronic Heart Failure and in Healthy Control Subjects
No. of Control
Subjects/Patients
Control Subjects Patients With Chronic HF
Total V˙O2
(ml/min)
Peak V˙O2/kg
(ml/kg per min)
Total V˙O2
(ml/min)
Peak V˙O2/kg
(ml/kg per min)
R
Coeff
p
Value
R
Coeff
p
Value
R
Coeff
p
Value
R
Coeff
p
Value
Age 31/100 20.55 0.001 20.56 0.001 20.47 , 0.0001 20.37 0.0001
LVEF 0/93 — — — — 0.07 0.5 0.027 0.8
Quadriceps strength 31/100 0.58 0.0006 0.5 0.003 0.53 , 0.0001 0.35 0.0003
Quadriceps CSA* 25/83 0.36 0.08 0.04 0.35 0.6 , 0.0001 0.29 0.007
Total muscle CSA* 25/83 0.38 0.058 0.12 0.55 0.66 , 0.0001 0.32 0.005
20-min fatigue 29/82 0.18 0.35 0.07 0.73 0.08 0.46 0.18 0.12
Furosemide equivalent dose 0/100 — — — — 0.11 0.28 0.12 0.2
*Correlations with muscle strength and size with data from weaker leg. Coeff 5 coefficient; — 5 not applicable; other abbreviations as in Tables 1 to 3.
Figure 2. Relation between thigh muscle CSA and maximal treadmill
V˙O2. Solid squares 5 patients with chronic HF (R 5 0.66, p , 0.0001,
n 5 76); open squares 5 control subjects (R 5 0.38, p 5 0.058, n 5
25).
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vation that strength per unit muscle is normal in chronic HF
differs from ours; the reason for this discrepancy may be
related to a different technique for assessing maximal isometric
strength or the smaller patient numbers.
There are several potential reasons for a reduction in
muscle bulk in CHF. Patients are less mobile than normal
subjects, and disuse atrophy may occur. Patients with chronic
HF are often anorectic and may be malnourished (9,26).
Additionally, catabolic factors, such as tumor necrosis factor
and other cytokines (27,28) and cortisol (29), are elevated in
chronic HF, and these factors in association with sympathetic
activation and insulin resistance (30) may result in muscle
protein loss.
The etiology of the reduced strength per unit muscle is also
potentially multifactorial. Some investigators have described
an increased fat content of muscle in chronic HF (11,31). Such
a fatty infiltration would result in an overestimate of effective
muscle CSA and a consequent apparent reduction of strength
per unit muscle. Other histologic changes observed in chronic
HF may be significant. Patients have an increase in the
percentage of type II fibers mainly as a result of increased type
IIb fibers. Type I fibers are probably reduced (16,32). In
addition, there appears to be a reduction in type II fiber
diameter, with some groups also reporting a reduction in type
I fiber diameter (11). Larsson et al. (33) in a study of 114
normal subjects found that the only independent histologic
variable that correlated with maximal isokinetic strength was
type II fiber area. Although the size of type II fibers correlated
with strength, it is unclear whether a reduction in type II fiber
diameter leads to a reduction in strength generated per unit
muscle. Possible changes in anatomic arrangement of muscle
fibers could also affect the strength per unit muscle.
Relation between muscle strength and bulk. We, like pre-
vious investigators (14), observed a highly significant correla-
tion between quadriceps CSA and strength in patients with
chronic HF. In normal control subjects, age is the strongest
predictor of strength, with quadriceps CSA failing to reach
significance as an independent predictor. It is likely that this
loss of the effect of age in chronic HF explains the greater
closeness of the relation between bulk and strength in chronic
HF. Age is no longer a significant predictor of strength in
chronic HF because the loss of muscle bulk and type II fiber
atrophy, which contributes to strength reduction in the elderly
(34), has already occurred in these patients. In our group of
normal control subjects, none of the measures of muscle size
predicted peak V˙O2 independently of age, which is consistent
with the findings of other investigators (35).
The significance of changes in muscle function. Muscle
indexes are related to body size. Any association between peak
V˙O2, which is weight adjusted, and muscle indexes, which are
not, will thus be weakened. To correct for this we considered
both absolute and weight-corrected peak V˙O2. In our patient
group, indexes of muscle bulk were significantly associated
with peak V˙O2 and were strongly correlated with absolute peak
V˙O2, with muscle CSA being an independent predictor of
absolute peak V˙O2. In chronic HF, therefore, it is muscle bulk
that has a significant effect on aerobic capacity. We, like other
investigators (12), found an association between muscle
strength and peak V˙O2. However, strength in chronic HF is
highly dependent on muscle CSA, with the association ex-
plained by the variation in muscle bulk.
Muscular fatigue occurred to a much greater extent in
patients with chronic HF than in control subjects. This finding
is consistent with those of other investigators. However, we
found no significant association with severity of chronic HF.
Minotti et al. (14) assessed dynamic endurance and noted that
it was reduced in chronic HF and correlated with peak V˙O2 but
that isometric (anaerobic) fatiguability did not. This second
measure of fatigue was probably closer to ours. In normal
subjects, resistance to isometric and dynamic endurance is
dependent on type I fibers (36). Patients with chronic HF have
a reduction in type I fibers, and it is possible that it is this
change in fiber type that leads in part to the increased fatigue
seen in patients with chronic HF.
Limitations of the study. The methods used to study
muscle function require maximal patient effort. It is possible
that with advancing heart failure, effort is reduced, resulting in
an apparent decrease in maximal strength. We attempted to
ensure maximal effort by the use of twitch interpolation, by
requiring patients to achieve a plateau in force generation and
by assessing several maximal contractions. We used CT scan-
ning as an estimate of muscle bulk. Although a relatively crude
measure, work from our own institution shows excellent cor-
relation between CT-based estimates of muscle bulk and
calculations of leg or total body lean tissue, using dual-energy
X-ray absorptiometry scanning (unpublished data). Finally, we
studied male subjects only, and our results may not be appli-
cable to female patients.
Conclusions. Patients with chronic HF have reduced quad-
riceps maximal isokinetic strength. This weakness occurs as a
result of both quantitative and qualitative abnormalities of the
quadriceps. With increasing exercise limitation of patients with
chronic HF, there is increased weakness, occurring mainly as a
result of loss of quadriceps muscle bulk. Muscular fatigue is
common in chronic HF but appears to be a feature of the
syndrome itself and does not relate closely to disease severity.
In patients with chronic HF, but not healthy control subjects,
muscle bulk is a determinant of peak V˙O2, which may explain
the lack of association between hemodynamic indexes and
exercise capacity in chronic HF. Taken together, these findings
suggest that in chronic HF peripheral changes rather than a
central hemodynamic disturbance limit exercise. Future ther-
apies aimed at increasing muscle bulk may thus be beneficial.
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